预约演示
更新于：2025-04-17
Luliconazole
卢立康唑
更新于：2025-04-17
概要
基本信息
药物类型 小分子化药 |
别名 Luconac Solution、Luliconazole (JAN/USAN/INN)、Lulifin + [12] |
作用方式 抑制剂 |
作用机制 fungal CYP51A1抑制剂(真菌细胞色素P450家族成员51抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H9Cl2N3S2 |
InChIKeyYTAOBBFIOAEMLL-REQDGWNSSA-N |
CAS号187164-19-8 |
关联
15
项与 卢立康唑 相关的临床试验IRCT20240711062393N1
Efficacy Evaluation of Loaded Nanostructured Lipid Carriers (NLC) with Luliconazole in Treatment-Resistant Dermatophytosis
CTRI/2024/03/063613
A Comparative study to evaluate the efficacy and safety of topical Luliconazole versus topical Ciclopirox olamine among patients with Tinea corporis/cruris - NIL
CTRI/2023/01/049161
A randomized study to evaluate and compare the efficacy of emollient versus topical luliconazole in the maintenance of remission of recurrent dermatophytosis after adequate systemic treatment.
100 项与 卢立康唑 相关的临床结果
登录后查看更多信息
100 项与 卢立康唑 相关的转化医学
登录后查看更多信息
100 项与 卢立康唑 相关的专利（医药）
登录后查看更多信息
285
项与 卢立康唑 相关的文献（医药）2025-03-05AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Eumycetoma Caused by Aspergillus terreus: A Case Report and Literature Review
Review
作者: Liu, Zhe ; Nakagawa, Ichiro ; Zhang, Mingrui ; Li, Fuqiu ; Hu, Xin ; Lv, Sha
ABSTRACT.:
Mycetoma is a granulomatous disease of subcutaneous tissue that is caused by different species of aerobic filamentous bacteria (actinomycetoma) or fungi (eumycetoma). Mycetoma treatment depends on the causative pathogen, and it mainly consists of antimicrobial interventions or surgery. Aspergillus terreus is an etiologic agent of invasive aspergillosis and a rare cause of eumycetoma that is common in central and southern China. The present case report describes a 45-year-old female patient with subcutaneous swelling and multiple active and healed sinuses over the dorsal aspect of the left foot who was diagnosed with eumycetoma caused by A. terreus. This is the first such case reported in China. We applied a combination treatment consisting of itraconazole with topical luliconazole cream and radiofrequency microneedling, and this was followed by significant regression of the lesion. In addition, we reviewed the current literature to summarize the epidemiological characteristics of mycetoma in mainland China and cases of eumycetoma caused by A. terreus worldwide.
2025-03-01JOURNAL OF DERMATOLOGY
Onychomycosis caused by Aspergillus species belonging to section Circumdati
Article
作者: Fukushima, Satoshi ; Hayashi, Daiki ; Kashiwada‐Nakamura, Kayo ; Makino, Katsunari ; Yaguchi, Takashi ; Matsumoto, Tadahiko ; Ohara, Sayaka ; Kubo, Masahide ; Noguchi, Hiromitsu
Abstract:
We encountered two cases of onychomycosis caused by Aspergillus (A.) subramanianii and A. sclerotiorum. These species belong to the Aspergillus section Circumdati, which is reportedly common in a wide range of habitats. The members of section Circumdati rarely cause onychomycosis. We report the second and fifth cases of A. subramanianii and A. sclerotiorum in the world. Positive findings in dermatophyte antigen kits helped us to diagnose these infections. These isolates were sensitive to ravuconazole, with a minimum inhibitory concentration of 0.5 μg/mL. They were successfully treated with oral fosravuconazole. We discuss 14 cases of onychomycosis caused by Aspergillus section Circumdati.
2025-03-01BRAZILIAN JOURNAL OF MICROBIOLOGY
Antifungal susceptibility, clinical findings, and biofilm resistance of Fusarium species causing keratitis: a challenge for disease control
Article
作者: de Aguiar Cordeiro, Rossana ; de Melo Guedes, Glaucia Morgana ; Rodrigues, Anderson Messias ; Milanez, Edlâny Pinho Romão ; Silva, Lua ; Santos Manzi de Souza, Pedro de Freitas ; de Andrade, Ana Raquel Colares ; Monteiro, Ruan Costa ; de Souza Collares Maia, Débora Castelo Branco ; Silva, Maria Laína
Fusarium keratitis (FK) is an important clinical condition that can lead to blindness and eye loss, and is most commonly caused by the Fusarium solani species complex (FSSC). This study evaluated the susceptibility of planktonic cells and biofilms of FSSC (n = 7) and non-FSSC (n = 7) isolates obtained from patients with keratitis from a semi-arid tropical region to amphotericin B (AMB), natamycin (NAT), voriconazole (VRZ), efinaconazole (EFZ), and luliconazole (LCZ). Analysis of clinical data showed that trauma was the most common risk factor for FK patients. Disease onset was longer in non-FSSC group (3-30 days) than in the FSSC group (3-7 days). FSSC strains were less susceptible to AMB and VRZ than non-FSSC strains (p < 0.05). Susceptibility to NAT, LCZ and EFZ was similar between isolates of FSSC and non-FSSC groups. Overall, patients infected with non-FSSC showed a better response to antifungal treatment. Corneal transplantation was more common in patients infected with FSSC (3/7) than in those infected with non-FSSC (1/7). Mature biofilms showed a poor response to antifungal treatment. Patients infected with Fusarium strains capable of forming antifungal tolerant biofilms had more complex therapeutic management, requiring two antifungals and/or corneal transplantation (p < 0.05). This study highlights the importance of mycological diagnosis and the antifungal susceptibility testing in the clinical management of FK. The ability of Fusarium to form antifungal tolerant biofilms poses a challenge to clinicians and urges the development of new antibiofilm therapeutics.
100 项与 卢立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 手癣 | 美国 | 2018-02-20 | |
| 甲癣 | 日本 | 2016-01-22 | |
| 皮肤念珠菌病 | 中国 | 2012-06-27 | |
| 真菌病 | 韩国 | 2010-02-01 | |
| 体癣 | 日本 | 2005-07-31 | |
| 股癣 | 日本 | 2005-07-31 | |
| 足癣 | 日本 | 2005-07-31 | |
| 念珠菌病 | 日本 | 2005-04-11 | |
| 癣 | 日本 | 2005-04-11 | |
| 花斑癣 | 日本 | 2005-04-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性皮肤黏膜念珠菌病 | 药物发现 | 美国 | 2011-01-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 75 | (Luliconazole Cream 1%) | 憲壓築鏇醖網齋製積廠(壓廠選壓廠遞鹽製夢餘) = 糧網鹹艱積網簾醖製醖 鹽襯遞蓋餘鹽觸夢齋憲 (襯餘糧窪鏇鏇範衊餘製, 2.93) 更多 | - | 2019-11-27 | ||
Vehicle Cream (Vehicle Cream) | 憲壓築鏇醖網齋製積廠(壓廠選壓廠遞鹽製夢餘) = 憲築製積鏇網廠憲窪鏇 鹽襯遞蓋餘鹽觸夢齋憲 (襯餘糧窪鏇鏇範衊餘製, NA) 更多 | ||||||
临床4期 | 30 | (Tinea Pedis) | 製顧願壓鑰遞鹹獵築遞(糧簾鏇選製艱鏇鏇窪願) = 繭願艱憲鑰壓襯獵鹽艱 鬱鬱窪選繭遞齋壓齋觸 (壓選觸壓製艱襯製選憲, 1.71) 更多 | - | 2019-11-27 | ||
(Tinea Cruris) | 衊蓋鏇憲憲窪選遞網鏇(繭顧選觸齋衊鹹鹽憲齋) = 糧鹹夢蓋繭繭齋積糧鏇 鏇夢齋製積壓齋簾製繭 (淵網膚選鬱廠獵鏇簾繭, 13.62) 更多 | ||||||
临床4期 | 20 | 艱襯蓋餘選齋夢襯願膚(顧鑰餘範鹹網壓淵壓顧) = 鹹鏇醖選構鹹襯簾窪顧 餘範襯網齋鹽鹹願壓膚 (獵夢壓構鏇遞壓簾選襯, 0) 更多 | - | 2019-11-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用